Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments
Launched by NEURONETICS · May 21, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how effective different mental health treatments have been for conditions like depression, obsessive-compulsive disorder (OCD), and anxiety. Researchers are examining information from past patients at Greenbrook to better understand the types of treatments used and how well they worked. They are currently recruiting participants to help with this study.
To be eligible, you must be between the ages of 18 and 65, and have received treatment for mental health issues at Greenbrook since 2011. Both men and women can participate, but only those whose information is complete in the database will be considered. If you join the study, you'll be contributing to valuable insights that could help improve mental health care in the future!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female reported in database and not an invalid entry
- • Age reported and not an invalid entry
- • Treatment date in 2011 or later.
- Exclusion Criteria:
- • • Incomplete information on treatment parameters
About Neuronetics
Neuronetics, a leading medical technology company, specializes in developing non-invasive solutions for neuropsychiatric disorders. With a focus on innovative therapies, Neuronetics is dedicated to advancing the field of neuromodulation through its flagship product, the NeuroStar® Advanced Therapy System, which utilizes Transcranial Magnetic Stimulation (TMS) to treat major depressive disorder. Committed to improving patient outcomes and enhancing the quality of life for individuals suffering from mental health conditions, Neuronetics actively engages in clinical trials to evaluate the efficacy and safety of its therapies, fostering a robust pipeline of research that underpins its mission to transform mental health treatment.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Malvern, Pennsylvania, United States
Patients applied
Trial Officials
Eleanor Cole, PhD
Study Director
Neuronetics
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported